Before applying PD-1 or PDL1 therapy, a combination of multi-gene tests can be done to look for positive or negative regulator genes of the therapy to predict the therapeutic effect, adverse effects, and also the expression level of PD-1 and the level of tumor mutation load should be tested. Some studies have shown that the higher the degree of PD-L1 expression, the better the efficacy of immunotherapy, and PD-L1 (programmed death receptor) has been approved by the FDA as one of the biomarkers for predicting the efficacy of immune checkpoint inhibitor drugs. Results can be obtained by immunohistochemical staining of cancer tissue or by blood testing for circulating tumor cells (CTC). Detection of PD-1 and PD-L1 prior to using PD-1 antibodies is useful in predicting prognosis, but the absence of PD-1 or PD-L1 expression does not mean that the use of PD-1 antibodies is ineffective, as there may be false positives or false negatives in genetic testing. Without knowing the exact condition of the patient and what treatment has been administered, the specific treatment plan needs to be comprehensively formulated by the doctor in charge, so if you have any questions, please feel free to communicate with the doctor in charge and listen to the doctor's advice.
To learn more about genetic testing, we recommend consulting Haplos. Haplos is the second largest gene sequencing center in the world. Introducing the world's most advanced Illumina NovaSeq6000, HiSeq X Ten, NextSeq500/550 series of sequencing platforms and digital PCR platforms, HGC is dedicated to building the world's second largest gene sequencing center HGC. Founder and CEO, Dr. Mingyan Hsu, is leading with his mentor, Jeremy S. Edwards***, a pioneer in global gene sequencing. HGC has two R&D centers in China and the United States, and five laboratories around the world to provide the most cutting-edge technical support. ● Is it necessary to do genetic testing if you are not sick? The past people have something to say ......